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Ketamine cystitis, also referred to as ketamine-induced uropathy, is a new clinical syndrome affecting
primarily young to middle-aged ketamine abusers and has become a global phenomenon since its ﬁrst
reported series in 2007. A spectrum of urological destructions ranging from mild cystitis to severely
contracted bladder, ureteric stricture, upper tract damage, and irreversible renal failure has been re-
ported. This review considers the scope and burden of ketamine cystitis in the Chinese population in
Asia, stating the current status of management pathway, and reviews our current understanding on the
pathophysiology of ketamine-induced uropathy.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Prevalence of ketamine cystitis among a Chinese
population
Since the ﬁrst report of street ketamine-associated cystitis
involving 10 young Chinese patients by the authors' team from
Hong Kong in 2007,1 more cases of the new clinical syndrome of
ketamine cystitis were subsequently reported from other Chinese
regions: Taiwan and China.2,3 The ﬁrst case series in mainland
China was from Nanfong Hospital, Guangzhou, China in 2008.2 As
for Taiwan, the ﬁrst reported case series was from Tri-Service
General Hospital, National Defense Medical Center, Taipei, Taiwan
in 2009.3 Extremely low market price and easy accessibility to the
drug havemade ketamine the drug of choice among young people.4
Furthermore, cracking down of ketamine trafﬁcking is particularly
difﬁcult, as it is legally produced and shipped for use in both human
and veterinary medicines, which can be easily diverted for illicit
purposes.5 This legal availability may help explain why ketamine
came to prominence as a recreational drug in the past number of
years.
The exact prevalence of ketamine cystitis, however, is difﬁcult to
measure numerically, because many drug abusers are poly-
substance abusers and most of them will not seek medical advicehe University of Hong Kong,
Kong Special Administrative
ociation. Published by Elsevier Tauntil they have severe symptoms. In addition, unless physicians
have a high index of suspicion to identify ketamine abuse as a
possible cause of lower urinary tract symptoms in young patients,
the diagnosis will otherwise be missed. A rough estimation of the
prevalence of ketamine cystitis among different Chinese pop-
ulations, however, may be possible from the statistics published
from respective government narcotic bureaus.
In Hong Kong, ketamine was ﬁrst seized in 1999 and has been
on top of the list of commonly abused psychotropic substances
since 2001.6 According to the Hong Kong Central Registry of Drug
Abuse Sixty-third Report, which gathered information from
various reporting agencies including local law enforcement de-
partments, drug treatment and rehabilitation centers, counseling
centers for psychotropic substance abusers, centers for drug
counseling of nongovernment organizations, youth outreach
teams of nongovernment organizations, and substance abuse
clinics under the Hospital Authority, ketamine remained the most
popular psychotropic substance being abused from 2004 to 2013,
with a peak of > 5000 abusers in 2009 (Fig. 1). When stratiﬁed by
age, the trend was also similar for young abusers under the age 21
years.7 The actual number of young ketamine abusers in recent
years, however, was not decreasing as it seemed to be, as more
abusers are “hidden ketamine abusers”d51% of abusers younger
than 21 years have admitted to have abused ketamine at home or
at friend's home in 2013, which is a substantial increase from 13%
in 2006.8
Regarding the proportion of ketamine abusers presenting with
lower urinary tract symptoms, a small scale survey conducted by a
psychotropic substance rehabilitation center in Hong Kongiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. Reported drug abusers of major types of psychotropic substances in Hong
Kong.7 MDMA ¼ methylenedioxylmethamphetamine.
W.-K. Ma, P.S.-K. Chu / Urological Science 26 (2015) 167e173168reported that ~30% of ketamine abusers had lower urinary tract
symptoms.9
As for Taiwan, according to the National Bureau of Controlled
Drugs, the 2014 International Narcotics Central Report, and local
Taiwan Bureau, ketamine abuse has been a growing problem in
Taiwan since 2008 and remains to be a popular party drug among
teenagers because of its low potential for addiction and absence of
criminal penalties for possession of a small amount (< 20 g). China
is the source of ~76% of the ketamine seized or sold in Taiwan.10e12
According to China's National Narcotics Control Commission
2014 Annual Report on Drug Control in China, ketamine is the
second most abused drug in China with seizures of 9.7 metric tons
of ketamine in 2013, compared to 4.7 metric tons in 2012.13
All in all, if 30% of the ketamine abusers in China, Taiwan, and
Hong Kong suffer from clinical manifestations of ketamine cystitis,
not only does this greatly impair the health conditions of the
affected individuals, but also imposes a huge burden on the public
health systemwith increasing numbers of hospital admissions and
dialysis requirements for possible upper tract damages.2. Management of ketamine uropathy in Hong Kong Chinese
population
2.1. Investigation pathway
A comprehensive clinical pathway has been established in some
urology centers pioneering in the study of this syndrome in the
region9 (Fig. 2). This includes detailed documentation of symp-
tomatology and quantiﬁcation by questionnaires, blood tests
(routine renal and liver function tests), urine tests (culture and
toxicology), urinary system ultrasonography, uroﬂowmetry, ﬂex-
ible cystoscopy, video urodynamic study, and computed tomogra-
phy for severe cases with possible upper tract involvement.
While pain symptoms can be represented by the widely used
visual analog scale (VAS) of 1e10, more comprehensive quantiﬁ-
cation of the symptoms are documented using standardized fre-
quency/voiding charts and the Pelvic Pain and Urgency/Frequency
(PUF) symptom scale. Developed by Parsons et al,14 the PUF
symptom scale questionnaire has been validated and used in
screening and diagnosing patients with interstitial cystitis. It
comprises seven questions concerning day- and night-time fre-
quency, pelvic/urological pain and its severity, and urgency and its
degree of severity. A symptom score and a bother score are
included, totaling a maximum of 35 points. In view of the clinical
and histopathological resemblance between interstitial cystitis andketamine cystitis,15 centers in Hong Kong adopted the PUF symp-
tom scale as an assessment tool for symptom quantiﬁcation in
these patients. A Chinese version of the PUF symptom scale (Fig. 3)
has been validated, and correlations with the symptomatology and
investigation results were evaluated.16 In the series comprising 50
patients with a mean age of 24 years and a mean duration of ke-
tamine abuse of 4.7 ± 2.8 years, the prevalence of urinary symp-
toms was as follows: urinary urgency (46 patients, 92%), frequency
(42 patients, 84%), nocturia (44 patients, 88%), dysuria (43 patients,
86%), and hematuria (34 patients, 68%).16 The same study suggested
that higher mean PUF total scores were noted in patients with
positive cystoscopic, urodynamic, and ultrasonographic investiga-
tion results, and a higher PUF score was associated with smaller
bladder capacity. The cutoff value of 17 is suggestive ofmore serious
urological sequelae: endoscopically conﬁrmed cystitis (83% vs.
47%), detrusor instability (48% vs. 0%), vesicoureteric reﬂux (14% vs.
0%), poor bladder compliance (48% vs. 0%), and hydronephrosis
(37% vs. 0%).
In a more recent series from the region involving 318 ketamine
abusers with a mean duration of 81 months of ketamine use, the
mean voided volume was 111 mL and the mean bladder capacity
was 152 mL, with a mean bladder emptying efﬁciency of 73%.17 In
more severe patients, the typical voided volume can be < 50 mL,
and these patients are napkin dependent because of severe urge
incontinence. In our earlier series, in which video cystometrogram
had been performed in 47 patients, the mean cystometric bladder
capacity was 154.5 mL (range 14e600 mL), with 51% (n¼ 24) of the
patients having a bladder capacity of  100 mL.9 Most of the pa-
tients showed decreased bladder compliance and/or detrusor
overactivity of different magnitudes at a very low bladder infusion
volume (as low as 14 mL). Of the patients, 13% showed vesicoure-
teral reﬂux as a secondary event to the severely contracted bladder
with high detrusor pressure. This ﬁnding correlated well with the
symptoms of these patients, in that both functional and cystometric
bladder capacities were markedly decreased, causing them to have
very frequent small voids.
Cystoscopy examination aims to reveal if there are any inﬂam-
matory and cystitis changes and the cause of hematuria, if any.
However, because of the small, painful bladder, this procedure is
not well tolerated by patients with severe symptoms if performed
under local anesthesia. To date, the largest series on cystoscopic
ﬁndings on ketamine abusers from the region involved 42 patients,
in which 30 patients had cystoscopy under local anesthesia, while
the others had cystoscopy and transurethral resection biopsy under
regional or general anesthesia.9 All patients showed various de-
grees of epithelial inﬂammation of the bladder and neo-
vascularization. Severe cases showed petechial hemorrhages, as
classically described in patients with interstitial cystitis. Histolog-
ically, there is mucosal ulceration, striking urothelial reactive aty-
pia, lamina propria inﬂammation with predominant lymphocyte
inﬁltration, and a variable number of eosinophils. Ultrastructural
examination by electronmicroscopy showed querciphylloid muscle
cells (vacuoles at the periphery of muscle cells; Fig. 4). This feature
has also been found in interstitial cystitis. In another UK series
involving 17 patients in whom cystoscopy and bladder biopsies
were performed, urothelial atypia with features mimicking carci-
noma in situ was noted in a signiﬁcant number of patients.18
Marked urothelial atypia was seen in the biopsy specimens of 12
patients with nuclear enlargement and loss of polarity. Immuno-
histochemistry for CK20, p53, and Ki67 was performed in 10 cases,
in which high expression of p53 was present in nine cases and that
of Ki67 was present in six cases. However, none of the biopsy
specimens showed expression of CK20 in the atypical urothelium,
which would be against carcinoma in situ. In addition, squamous
metaplasia, nephrogenic metaplasia, and calciﬁcation have been
Fig. 2. Clinical pathway for management of ketamine cystitis patients. PUF¼ Pelvic pain and Urgency/Frequency; VAS ¼ visual analog scale.
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its underlying pathophysiology, as the mechanism of chronic
interstitial inﬂammation by ketamine metabolites is the main area
of on-going research based on current histology ﬁndings.2.2. Management options
2.2.1. Abstinence from ketamine use
The single most important step in the management of ketamine
uropathy or cystitis is obvious: cessation of ketamine abuse. While
a doseesymptom relationship between ketamine use and symp-
tomatology occurrence has been established,20 abstinence from
ketamine abuse is essential in protecting the urological system
from further damage. Medication therapy, intravesical instillations,
urinary diversion, and surgical treatment options have all been
suggested,1e3,9,21e24 but management of the condition remains a
great challenge to urologists. The difﬁculty in management is
attributed not only to the relatively unclear pathophysiology, but
also to complex psychosocial factors. Although cessation of the use
of soft drugs such as ketamine and phencyclidine would not lead to
physical withdrawal symptoms, many ketamine abusers are poly-
drug abusers, and it is difﬁcult to eliminate their psychological
dependence on the drugs by their own efforts.25e27 A multidisci-
plinary approach, preferably by a team of related professionals,
would increase the success rate in following up and dealing with
the complex psychosocial as well as physical problems in these
abusers. In 2009, an outreach team of volunteers comprising psy-
chiatrists, urologists, physiotherapists, nurses, and social workers
performed a screening evaluation of ketamine abusers outside the
setting of a hospital at night time andwere able to get in touchwith
66 young adults socializing in community centers in Hong Kong.28
Evaluation of these abusers revealed that for individuals after 1year of abstinence, the PUF scores were signiﬁcantly lower and
voided volumes were higher than those for active abusers. Good
rapport building with abusers is the key to success in treating the
condition.
2.2.2. Medication therapy
Different medications have been advocated in treating ketamine
cystitis, including oral antibiotics, nonsteroidal anti-inﬂammatory
drugs, anticholinergics, steroids, amitryptiline, hydroxyzine, and
pentosan polysulfate.1e3,9,21e23 However, most of the oral medica-
tions fail to achieve good symptomatic relief in patients, and even if
they do, the effect is transient; none of these medications can
reverse the detrimental effects of ketamine use on the bladder once
ﬁbrosis has taken place. Pentosan polysulfate has been shown to
have more sustaining symptomatic relief in some patients who
failed steroid and antibiotic therapies.21 It is postulated that this
drug can help replenish the denuded urothelial layer of the bladder
mucosa, as in patients with interstitial cystitis/bladder pain syn-
drome. However, it is unclear whether the relief was resulted from
ketamine abstinence, use of pentosan polysulfate, or a combination
of both. No comparative studies were available to further prove the
efﬁcacy of individual medication therapy.
2.2.3. Intravesical instillation/hydrodistension therapy
With the small, contracted bladder as a common ﬁnding in
ketamine cystitis patients, intravesical instillation of medications
and/or hydrodistension therapy has been suggested for directly
improving the damaged glycosaminoglycan layer in the bladder
mucosa and increasing the bladder capacity, as in interstitial
cystitis.29,30 Rescue instillations with diluted lignocaine followed by
hydrodistension with normal saline, or intravesical instillation of
sodium hyaluronic acid, have been studied and showed
Fig. 3. Validated Chinese version of the Pelvic Pain and Urgency/Frequency symptom scale.
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sodium hyaluronic acid instillation, conducted in Hong Kong
among 12 ketamine abusers with severe symptomatology (mean
PUF score¼ 28.7 out of 35,mean VAS score¼ 6.7 out of 10) and very
small bladder capacity (mean cystometric bladder
capacity¼ 64.8 mL), with weekly intravesical instillation of sodium
hyaluronic acid for at least 6 weeks, has shown signiﬁcant
improvement in all the studied parameters (mean PUF 21.2, mean
VAS 4.9, and mean cystometric bladder capacity 125.8 mL) and that
the effects have been sustained on the mean follow-up of > 2
years.31 Although it would be difﬁcult to ascertain that the results
were not contributed by ketamine abstinence alone, this treatment
option has been shown to be safe and can be tolerated in ketamine
abusers.
2.2.4. Urinary diversion and upper tract protection
Hydronephrosis occurs in a signiﬁcant proportion of chronic
ketamine cystitis patients, ranging from 13% to 50%.9,32e34 The
proposed mechanisms include ureteric reﬂux secondary to detru-
sor overactivity and/or a poor compliance bladder, and ureteric
stricture related to ketamine use. Interventions such as percuta-
neous nephrostomy for renal impairment were required in ~5% of
the presenting patients.9 Every effort has to be paid in protecting
the upper tract damage, although the young adults have poor
acceptance and compliance to percutaneous nephrostomy
drainage, and the blockage or dislodgement rate is high. Antegradeor retrograde stenting was an alternative treatment for hydro-
nephrosis and renal impairment secondary to reﬂux, although the
stent tip may irritate the bladder and, in turn, cause more irritative
urinary symptoms or hematuria.35 Long-term metallic ureteric
stenting has also been recently reported.36
In our experience, endourological procedures in treating
ureteric strictures (if any) in these patients have been difﬁcult, as
most of them suffer from long and tight strictures because of
chronic inﬂammation and ﬁbrosis. The choice of deﬁnitive recon-
struction surgery in these patients is often limited by the
concomitant small contracted bladder. More sinister disease course
has been observed in a handful of ketamine abusers in the region,
who developed end-stage renal failure and required dialysis. This
has indeed a signiﬁcant inﬂuence on the burden in the health care
system and the society.
2.2.5. Augmentation cystoplasty/neobladder reconstruction
Reconstruction of the ﬁbrotic, small bladder with augmentation
cystoplasty has been performed in nine patients in three different
centers in Hong Kong, with the initial four cases being published
previously.24 Their outcomes varied. Although the patients
abstained from ketamine usage prior to surgery, many of them
resumed usage at different stages after surgery. Four of them
developed serious complications, including renal failure, convul-
sion, and ureteric strictures. One of the possible causes for the rapid
development of complications was recirculation of ketamine and
Fig. 4. (A,B) Ketamine-associated cystitis shows a variable degree of inﬂammation. (C) The inﬁltrates comprise predominantly lymphocytes and a variable number of eosinophils.
(D) Ultrastructural examination shows querciphylloid muscle cells. Note. From “The destruction of the lower urinary tract by ketamine abuse: a new syndrome?” by P.S. Chu, W.K.
Ma, S.C. Wong, R.W. Chu, C.H. Cheng, S. Wong S, et al, 2008; BJU International, 102, p. 1616e22. Copyright 2008/ W.-K. Ma and P.S.-K. Chu. Adapted with permission.
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augmentation. Therefore, careful selection of patients and repeated
emphasis on the maintenance of abstinence are important steps
prior to surgery.
While preservation of part of the bladder would potentially
retain the bladder pain symptoms, some propose removal of the
whole bladder with cystectomy, followed by neobladder recon-
struction.37 Detailed counseling regarding, as well as assessment of,
the patient's compliance to postoperative care and dignity on ke-
tamine cessation after surgery is necessary in order to avoid poor
outcomes of the ultramajor procedure.
3. Understanding the pathophysiology of ketamine cystitis
The exact pathophysiology of ketamine uropathy is still un-
known, despite the efforts made in gathering clinical, biochemical,
and histological evidences together with laboratory and animal
studies. Our current knowledge is that ketamine or its metabolites,
being primarily excreted in urine, induce an initial acute inﬂam-
matory reaction of the urothelium, which starts a chain reaction
that eventually results in bladder damage, such as epithelium
denudation, ulceration, submucosal inﬂammation, and ﬁbrosis. A
recent Taiwan study has revealed elevated serum immunoglobulin
E levels in ketamine cystitis patients compared with interstitial
cystitis patients, bacterial cystitis patients, and controls.38 This
suggests that hypersensitivity may play an important role in the
pathogenesis of ketamine uropathy.
3.1. In vitro studies
Two in vitro cell line studies from Taiwan and mainland China
have demonstrated the detrimental effect of ketamine in inducing
apoptosis in a dose- and time-dependent manner.39 Ketaminearrested the cells in G1 phase and increased the sub-G1 population,
which could be the mechanism of urothelium damage, increasing
barrier permeability to other toxic substances. The cytotoxicity of
ketamine has indeed also been reported in neuroblastoma,40,41
lymphoma Jurkat cells,41 and hepatoma.42
3.2. In vivo studies
Five animal in vivo studies have been reported to date on the
topic with three mouse and two rat models.39,43e46 Summarizing
the key ﬁndings from these studies, it has been shown that keta-
mine can induce the following changes: (1) submucosal inﬁltration
of mononuclear inﬂammatory cells; (2) thinning of urothelium and
a reduction in the number of nerve ﬁbers; (3) a decrease in the
mouse body weight growth rate and bladder capacity; (4) an in-
crease of adenosine triphosphate-evoked detrusor contraction and
P2X1 receptor protein; (5) increase of phosphorylated transgelin of
bladder smooth muscle; (6) induction of cyclooxygenase-2 and
inducible nitric oxide synthase gene expression; and (7) down-
regulation of a total of 52% of keratin family genes, particularly
keratin 6a, 13, and 14. All these changes give further insights for us
to understand the pathophysiology of ketamine uropathy, although
human bladder physiology is much more complex and multiple
mechanisms may come into play after chronic ketamine exposure.
4. Resources and direction on lowering the burden
In Hong Kong, since the publication of the ﬁrst report of 10
patients with ketamine cystitis in 2007,1 the Government of the
Hong Kong Special Administrative Region has provided tremen-
dous ﬁnancial support to antiketamine abuse research on clinical
and basic laboratory science, projects on raising community and
school awareness, and rehabilitation.47 Besides, enhanced law
W.-K. Ma, P.S.-K. Chu / Urological Science 26 (2015) 167e173172enforcement by the Hong Kong Judicial Bureau on drug trafﬁcking
of ketamine since 2008 had helped reduce ketamine supply in the
territory (Table 1).48,49
The burden on the society arising from ketamine abuse is a vi-
cious cycle: it starts as a social problemwhen young people begin to
abuse ketamine, who are then complicated by urological conse-
quences that may be irreversible and, in turn, create more social
and economic problems.
One of the clinical projects supported by the Beat Drugs Fund in
Hong Kong is a prospective longitudinal study on the outcomes of
various treatment modalities under a standardized protocol in
patients suffering from ketamine-induced voiding dysfunction.50
This study concluded that both anti-inﬂammatory drugs and an-
algesics could effectively alleviate symptoms of ketamine cystitis.
However, abstinence from ketamine usage and the amount of ke-
tamine consumed remained two important factors determining the
response to treatment as well as symptom relief.
Another large-scale project supported by the Beat Drugs Fund
was establishment of the Youth Urological Treatment Centre in
2011.51 This center involves a multidisciplinary team with experts
from all ﬁelds: social workers, pediatricians, clinical psychologists,
psychiatrists, urologists, occupational therapists, and more impor-
tantly patients' family members. The mission is to provide early
urological assessment and treatment to young patients suffering
from ketamine-associated uropathy, and to formulate a practical
and cost-effective management protocol by concentrating the
experience in a single center. The center had beneﬁtted over 300
patients in 2 years.17
Among the many community projects supported ﬁnancially by
the Beat Drugs Fund, the project named “A community study of
uro-psycho-physical changes in young adults using ketamine” led
by urologists, with coinvestigators involving other paramedical
health personals, provided data on community-based prevalence of
ketamine cystitis.20,28,52
Several basic laboratory scientiﬁc research projects funded by
the Beat Drugs Fundweremostly animal model studies of ketamine
abuse, which aimed at explaining the pathophysiology of damaging
effects of ketamine on the urinary system.53
All in all, the future direction of resource allocation and studies
will most likely be multinational, multidisciplinary clinical and/or
basic scientiﬁc studies, hoping to provide understanding on the
pathophysiology of ketamine cystitis and also to formulate a Chi-
nese or an Asian guideline on diagnostic, investigation, and treat-
ment protocols. By providing effective clinical treatment, and co-
operating with other specialties (psychiatrists, social workers,
occupational therapists, and nurse counselors), urologists will be
able to offer rehabilitation opportunities to these patients with the
aim of reintegrating them into the society. To achieve this, the
government of every region should play the paramount role of
coordinating different bureaus (such as education, police, andTable 1
Change in HKSAR's sentence tariffs for trafﬁckers in ketamine before and after June
2008.48
Years of imprisonment Before June 2008 (g) After June 2008 (g)
Within sentencer's discretion  25  1
2e4 25e400 1e10
4e6 10e50
4e8 400e800
6e9 50e300
 8 > 800
9e12 300e600
12e14 600e1000
 14 > 1000
HKSAR¼Hong Kong Special Administrative Region.judicial departments), counseling centers for psychotropic sub-
stance abusers, antidrug volunteer groups, and family support
groups in combating drug abuse.Conﬂicts of interest
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